ライフサイエンスコーパス: cell proliferative

1 vestigation examined if combined efficacy of cell proliferative ability of rhEpo along with the neuro

2 heir viability and caused an increase in the cells' proliferative ability.

3 we show here that they displayed a range of cell-proliferative abnormalities, including decreased bo

4 l mechanisms by producing anti-apoptotic and cell proliferative actions.

5 f treatment, reduction of colonic epithelial cell proliferative activity (P<.05), reduction in size o

6 labeling index (PCLI) is a measure of plasma cell proliferative activity and is an important prognost

7 155 expression required for maintaining Treg cell proliferative activity and numbers under nonlymphop

8 specific suppression of ex vivo anti-donor T-cell proliferative activity and reductions in interferon

9 broblasts and fibroblasts may limit T-helper cell proliferative activity in the gut and, thus, might

10 gradation time in vivo; reduced sensitized T-cell proliferative activity in vitro; reduced IL-2, IFN-

11 ganisms, and IgG anti-rSEC neutralized the T-cell proliferative activity of native SEC.

12 in-binding motif that serves to regulate the cell proliferative activity of the paracrine hormone, an

13 This suppression of cell proliferative activity was attenuated by N-acetyl c

14 testinal secretion and intestinal epithelial cell proliferative and apoptotic homeostasis.

15 as negatively associated with HBV-specific T-cell proliferative and CD8 responses during treatment, e

16 HBV core-specific T-cell proliferative and CD8 responses were more vigorous

17 draining lymph node cells were tested for T cell proliferative and cytokine responses against the di

18 , marked reductions in OVA-specific CD4(+) T cell proliferative and cytokine responses in spleen and

19 tory T cells (CD4(+)CD25(hi)FoxP3(+)), and T-cell proliferative and cytokine responses to anti-CD3/CD

20 Second, in vitro CD4 T-cell proliferative and cytokine responses to HIV-specifi

21 ed to undetectable levels and increases in T cell proliferative and cytokine responses to microbial a

22 T-cell proliferative and cytokine-producing capacities wer

23 At day 30, antidonor T-cell proliferative and cytotoxic responses and both comp

24 However, SAHA had no effect on donor T cell proliferative and cytotoxic responses to host antig

25 y diminished capacity to induce allogeneic T-cell proliferative and cytotoxic responses.

26 ice possessed reduced splenic OVA-specific T cell proliferative and delayed-type hypersensitivity res

27 of donor-reactive CD4(+) T cells uncouples T cell proliferative and effector cytokine production from

28 as associated with an enhanced Ag-specific T cell proliferative and functional response.

29 urified recombinant Mtb39A elicited strong T-cell proliferative and gamma interferon responses in per

30 epitopes elicited potent effector/memory Th cell proliferative and IFN-gamma responses, including th

31 at the plasma membrane, effects of PLSCR1 on cell proliferative and maturational responses may also r

32 eptor, and apoptotic) and adaptive (CD4(+) T-cell proliferative and memory interleukin 17A) responses

33 SiLAT1 and JPH203 suppressed cell proliferative and migratory and invasive abilities

34 bovine heart PDC (bPDC) in adjuvant showed T-cell proliferative and mixed Th1/Th2 cytokine secretory

35 Significant levels of OVA-specific CD4(+) T cell proliferative and OVA-induced Th1- and Th2-type cyt

36 Significant levels of PspA-specific CD4(+) T cell proliferative and PspA-induced Th1- and Th2- type c

37 rimeric G protein signaling is important for cell-proliferative and glucose-sensing signal transducti

38 onal for either MCP-1 or CCR2 had suppressed cell-proliferative and Th1 responses following oral admi

39 nthetic gene that encodes for 12 B cell, 6 T cell proliferative, and 3 cytotoxic T lymphocyte epitope

40 oantibody formation, clinical, histologic, T cell proliferative, and cytokine responses were evaluate

41 Further, high T-cell-proliferative- and delayed-type hypersensitivity re

42 tients with measurable lymphoma, 8 mounted T-cell proliferative anti-Id responses, and 4 had clinical

43 sistent with the observed phenotype of tumor cell proliferative arrest and death and endothelial cell

44 ed activities of PTEN are required for stalk cells' proliferative arrest.

45 , we tested responses in an immunoblot and T-cell proliferative assay to distinguish type 1 diabetic

46 T-cell proliferative assays and cytokine assays using lymp

47 replication did not depend on differences in cell proliferative capabilities, cell surface expression

48 uman keratinocyte migration while preserving cell proliferative capability.

49 8 microM) and CD71 (IC50; 1.6 microM), and T-cell proliferative capacities measured by proliferating

50 owth factor (EGF)-induced cell migrative and cell proliferative capacities, as reported previously.

51 mportant contributor to sarcoidosis CD4(+) T-cell proliferative capacity and clinical outcome.

52 igating immune function in NOD2(-/-) mice, T cell proliferative capacity and IL-2 production were not

53 at p16 is the primary determinant of the NHP cell proliferative capacity and that hTERT is required f

54 how that age-dependent changes in supporting cell proliferative capacity are due in part to changes i

55 th impairment of resident cardiac progenitor cell proliferative capacity associated with altered cano

56 that T cells completed, no change in the per cell proliferative capacity of the remaining Ag-specific

57 method of extending telomeres and increasing cell proliferative capacity without risk of insertional

58 of plasma LPS in vivo significantly alter T cell proliferative capacity, monocyte cytokine release,

59 in and determined the effects of acrolein on cell proliferative capacity, senescence-associated beta-

60 ), evidence of thymopoiesis, and sustained T-cell proliferative capacity.

61 -regulated kinases (ERK1/2), it mediates the cell-proliferative, cell-growth, and survival-promoting

62 IHH, and bFGF) failed to rescue endothelial cell proliferative control but collectively promoted vas

63 transcriptional activity and enrolls Hox in cell proliferative control.

64 rrelated with down-regulation of TNF-induced cell-proliferative (COX-2 and cyclin D1) and antiapoptot

65 Thereafter, mycobacterial Hsp65-specific T cell proliferative, cytokine, and antibody responses wer

66 Furthermore, T(reg) removal eradicates T-cell proliferative defects and reverses T(H)2 cytokine s

67 T cell proliferative defects induced by sTat in vitro can

68 racellular isoAsp proteins associated with T cell proliferative defects of MRL autoimmune mice.

69 fore constitute a new therapeutic target for cell proliferative diseases such as atherosclerosis.

70 e (PNP) and that human PNP is a target for T-cell proliferative diseases.

71 a systemic survey to exclude systemic plasma cell proliferative diseases.

72 ) multiple myeloma is an asymptomatic plasma-cell proliferative disorder associated with a high risk

73 significance (MGUS) is a premalignant plasma-cell proliferative disorder associated with a life-long

74 NSG recipients, but produced a monoclonal T-cell proliferative disorder similar to T-ALL.

75 ignificance (MGUS) is an asymptomatic plasma cell proliferative disorder with a lifelong risk of prog

76 kemia (pPCL) is a rare and aggressive plasma cell proliferative disorder with a very poor prognosis a

77 Plasma cell proliferative disorders are frequently associated w

78 and mutations in DNMT3A correlate with mast cell proliferative disorders in humans, the role of DNA

79 and its analogues may be useful for treating cell proliferative disorders such as cancer.

80 ith extrahepatic manifestations (diabetes, B-cell proliferative disorders, depression, cognitive diso

81 persons with lymphoproliferative and plasma cell proliferative disorders, suggesting presence of sha

82 activated T-cells, making it a target for T-cell proliferative disorders.

83 t-chain amyloidosis, or other related plasma-cell proliferative disorders.

84 This assay has prognostic value in plasma cell proliferative disorders.

85 ted organs and tissues of patients with mast cell proliferative disorders.

86 a fluorescent dye to dissect and quantify T cell proliferative dynamics in vivo.

87 However, the casual link between cell proliferative effects during liver regeneration and

88 n signaling pathway, we hypothesize that the cell proliferative effects of hamartin and tuberin are p

89 in-Barr virus (EBV) oncogenes exert potent B cell proliferative effects.

90 of Rev-erbalpha in vivo augmented satellite cell proliferative expansion and regenerative progressio

91 , resulting either in activation-dependent T cell proliferative expansion and survival or in the acce

92 epletion abrogated antigen-specific CD8(+) T cell proliferative expansion, transforming subclinical c

93 surrogate light chain (SLC), signals pre-BII-cell proliferative expansion.

94 nding that METT-10 functions to inhibit germ-cell proliferative fate, despite promoting mitotic cell

95 rm line to inhibit the specification of germ-cell proliferative fate.

96 Conventional paradigm ascribes the cell proliferative function of the human oncoprotein mou

97 vity and the expression of antiapoptotic and cell-proliferative gene products.

98 e we adapt a dye dilution assay for tracking cell proliferative history through mass cytometry and un

99 generated high-titer immunoglobulin G and T-cell proliferative immune responses against CEA.

100 nsfectants had fewer vessels and lower tumor cell proliferative indices than tumors in the other grou

101 cient mice displayed a relative reduction in cell proliferative indices, as well as increased tumor n

102 a are the first to reveal that the target of cell proliferative inhibitory action of OGF in human HNS

103 with controls, patients with CHB had weak T-cell proliferative, interferon gamma, and interleukin 10

104 ich is characterized by complex, endothelial cell-proliferative lesions of lung precapillary arteriol

105 c potential of tumor cells by increasing the cell proliferative, migratory, and invasive capacities.

106 ion of the epithelium through stimulation of cell proliferative, migratory, and wound healing respons

107 patients mounted either humoral (n = 4) or T-cell-proliferative (n = 4) responses to the MsIg compone

108 Here, we examined the cell proliferative, neurogenic, and behavioral effects o

109 We examined the cell proliferative, neurogenic, and behavioral effects o

110 furcated mechanisms of signaling to a common cell proliferative pathway.

111 is removed, rebound activation of MET-driven cell proliferative pathways and tumor growth may occur,

112 ry is linked to tumor suppression as well as cell-proliferative pathways and that the reestablishment

113 the mast cell compartment results in a mast cell proliferative phenotype in mice, demonstrating that

114 tandard transplantation conditions, the stem cell proliferative potential is not compromised during h

115 rmis is due to slowing of the epidermal stem cell proliferative rate.

116 lating their BCRs well before a detectable B cell proliferative region appeared at the follicle base.

117 ld increase in the median p24-induced CD4+ T-cell proliferative response and a 57% increase in the nu

118 of E4 and E1 had little impact on the CD4 T-cell proliferative response and cytolytic activity of CD

119 creased its effectiveness in costimulating T cell proliferative response and early IL-2 production in

120 The in vitro splenic T cell proliferative response and induction of IFN-gamma t

121 ells, B cells, or natural killer cells, or T-cell proliferative response compared with interferon bet

122 kground resulted in a dramatically reduced B cell proliferative response following IgM ligation, char

123 Our results suggest that the inhibition of T cell proliferative response in microgravity culture is a

124 of GFAP filament assembly and inhibition of cell proliferative response in Muller glia.

125 ptophan (1-mT) results in increased CD4(+) T-cell proliferative response in PBMCs from HIV-infected p

126 developmental abnormality in the epithelial cell proliferative response in those mice.

127 eta fusion cells failed to induce a strong T cell proliferative response in vitro, mainly due to the

128 ally, both internalization of CD26 and the T cell proliferative response induced by CD26-mediated cos

129 The results suggest that a strong T-cell proliferative response is induced upon rechallenge

130 The prevention of a myeloma cell proliferative response resulting from inhibition of

131 d of infected individuals, inhibited human T cell proliferative response through interaction with the

132 In addition, the T-cell proliferative response to allogeneic LC-derived mDC

133 f T-cell tolerance was assessed by splenic T-cell proliferative response to antigen at 5 weeks.

134 wild-type C57BL/6 mice and had an enhanced T cell proliferative response to bovine CII.

135 EGF-like growth factor (HB-EGF) in the beta-cell proliferative response to glucose, a beta-cell mito

136 The T-cell proliferative response to HBcAg did not differ betw

137 ne viral load or CD4+ T cell count and the T cell proliferative response to HIV-1 Gag.

138 iency only partially reduced the naive CD8 T cell proliferative response to IL-15/IL-15Ralpha complex

139 as associated with a significantly reduced T cell proliferative response to mycobacterial Hsp65, whic

140 RS-1 nor IRS-2 overexpression induced a beta-cell proliferative response to TGF-alpha/EGF.

141 cretion and were unable to induce a normal T cell proliferative response to TT.

142 detected by inhibition of the Ag-specific T cell proliferative response upon Ag presentation by IFN-

143 ability to transduce CLL cells, a vigorous T-cell proliferative response was obtained using cells tra

144 ed subsets of lymphocytes and quantitative T-cell proliferative response were assessed in an explorat

145 and/or SRL both in vitro (by inhibiting of T-cell proliferative response) and in vivo (by inhibiting

146 Despite a compensatory beta-cell proliferative response, beta-cell mass progressivel

147 Human HSCs did not stimulate allogeneic T-cell proliferative response, indicating that they are no

148 cells, and elicits a robust TLR9-dependent B cell proliferative response.

149 also abolishes primary mitogen-induced liver cell proliferative response.

150 g a significant HER-2/neu protein-specific T-cell proliferative response.

151 , that generated a low-level but clear-cut T cell proliferative response.

152 s nor everolimus could inhibit the CD4CD28 T-cell proliferative response.

153 Although we found both a high CD4(+) T cell-proliferative response and TH2 cytokines production

154 mg/kg APAP, these changes plus a potentiated cell-proliferative response are necessary for protection

155 munization, respectively), in increases in T cell-proliferative response to HPV-16 L1 VLPs (P<.001).

156 rosis, but had no inhibitory effect on the T cell-proliferative response to myelin basic protein (MBP

157 sole class II molecule generated a robust T cell-proliferative response when primed with peptide 2 o

158 amma, TNF-alpha, and IL-6 in the augmented T cell-proliferative response.

159 dose levels of vaccine, peptide-specific, T-cell proliferative responses (n = 3) and/or DTH response

160 dendritic cell responses (flow cytometry), T-cell proliferative responses (thymidine incorporation),

161 nges paralleled reduced IL-2 secretion and T cell proliferative responses after TCR-CD28 stimulation

162 onstruct produced antibodies and exhibited T-cell proliferative responses against core or envelope.

163 The frequency of T-cell proliferative responses against VP2 was significant

164 ignificantly increased autoantigen-induced T cell proliferative responses along with greater numbers

165 characterized by antigen-specific impaired T cell proliferative responses and a distinct pattern of c

166 e treated with recombinant Map had reduced T cell proliferative responses and a significantly reduced

167 mpared with Ab positivity, we assessed the T-cell proliferative responses and Ab responses (islet cel

168 raft histopathology as well as anti-HLA-A2 T-cell proliferative responses and anti-HLA-A2 antibody de

169 B-cell proliferative responses and differentiation to immu

170 Allogeneic C3H/HeJ (C3H; H2k) T-cell proliferative responses and generation of cytotoxic

171 T-cell proliferative responses and immunoglobulin G antibo

172 ration of T-regulatory cells that suppress T-cell proliferative responses and induce tolerance.

173 insight into how TNF may inhibit endothelial cell proliferative responses and modulate angiogenesis i

174 significant levels of OVA-specific CD4(+) T cell proliferative responses and OVA-induced IFN-gamma a

175 n, significant levels of OVA-specific CD4+ T cell proliferative responses and OVA-induced IL-4 and IL

176 In the mucosa, both Peyer's patch T cell proliferative responses and OVA-specific fecal IgA

177 In contrast, Th cell proliferative responses and secretion of cytokines

178 lsed DC can induce both E7-specific CD4(+) T-cell proliferative responses and strong CD8(+) CTL respo

179 Ex vivo grass antigen-driven T-cell proliferative responses and the frequency of IL-4(+

180 The results suggest that HHV-8 T cell proliferative responses are common in HIV-negative

181 llergen-driven IL-4(+) CD4(+) T cells, and T-cell proliferative responses are detectable in the perip

182 present on the surface of donor DCs, donor T cell proliferative responses are generated only in respo

183 T-cell proliferative responses are inhibited during the er

184 HIV-1-specific CD4+ T cell proliferative responses are not measurable in most

185 as negatively associated with HBV-specific T-cell proliferative responses at both time points.

186 y positions induced enhanced specific CD4+ T cell proliferative responses at lower peptide concentrat

187 eneic MLRs between DCs and T cells reduced T cell proliferative responses but did so less efficiently

188 Suppression of CD4(+) T cell proliferative responses by both CD25(+) and CD25(-)

189 e formation prior to the induction of full T cell proliferative responses by concurrent indirect Ag p

190 ory T cells that more efficiently suppress T cell proliferative responses by mixed leukocyte reaction

191 s showed enhanced suppressive activity for T cell proliferative responses compared with freshly isola

192 d activation of beta-catenin, and epithelial cell proliferative responses during C. rodentium infecti

193 284, 295-314, and 305-324) elicited strong T-cell proliferative responses from all strains of mice wh

194 re, both the magnitude of p24-induced CD4+ T-cell proliferative responses from CD8-depleted PBMC and

195 These p24-induced CD4+ T-cell proliferative responses from CD8-depleted PBMC were

196 emonstrated CMV-specific CD4(+) and CD8(+) T cell proliferative responses from PBMC, with CD4(+)IFN-g

197 Interestingly, most HCV-specific CD4 T-cell proliferative responses in AA patients were unaccom

198 HIV-1 Ag-specific CD4(+) T cell proliferative responses in human subjects with adva

199 the CTLp frequency, anti-NP Ab titers, and T cell proliferative responses in mice that were injected

200 f-life becomes apparent during analyses of T cell proliferative responses in mice, particularly when

201 epitope, peptide 5 (P5), stimulates strong T cell proliferative responses in subjects with delayed (D

202 rtial BAFF neutralization rescues aberrant B cell proliferative responses in such mice.

203 nd TILN immunization induced specific CD4+ T cell proliferative responses in the iliac lymph nodes, w

204 Like C1q, HCV core can inhibit T-cell proliferative responses in vitro.

205 sing of DC to efficiently trigger specific T-cell proliferative responses in vitro.

206 nization with this construct elicited CD4+ T cell proliferative responses in vivo.

207 CD4(+) T-cell proliferative responses indicative of breakdown of

208 CMX-13 inhibited T cell proliferative responses induced by Con A and alloan

209 The peripheral blood T cell proliferative responses induced by topo I and in vi

210 Peripheral blood mononuclear cell proliferative responses of 25 controls and 10 patie

211 T cell proliferative responses of B6.129S1-IL-12rb2(tm1Jm)

212 nd inguinal lymph nodes, without affecting T cell proliferative responses or levels of anticollagen a

213 anergy to recall antigens and lower (<70%) T-cell proliferative responses than controls after activat

214 lowered serum autoantibody levels, reduced T cell proliferative responses to AChR, and an expansion i

215 immunocompromised, with reduced polyclonal T cell proliferative responses to alloantigen, defined pep

216 17 receptor (R):Fc fusion protein inhibits T-cell proliferative responses to alloantigens and prolong

217 m four different colonies side-by-side for T-cell proliferative responses to an expanded panel of aut

218 T cell proliferative responses to diabetes-associated Ags

219 We compare changes in lymphocyte subsets, T cell proliferative responses to disease-associated targe

220 iltration into grafts but not with altered T-cell proliferative responses to donor stimulators.

221 The induction of CD4+ T cell proliferative responses to eight synthetic peptides

222 iding sufficient help to allow optimal CD8 T cell proliferative responses to exosomal protein.

223 /- --> F1 chimeras were also able to mount T-cell proliferative responses to foreign antigens equal t

224 rst, neither APC type was able to initiate T cell proliferative responses to full-length native Topo

225 The human T cell proliferative responses to GA were HLA class II DR-

226 nd untreated MS patients exhibit prominent T cell proliferative responses to GA.

227 kinase proto-oncogene, reportedly modulates cell proliferative responses to growth factors, contract

228 T-cell proliferative responses to HER-2/neu peptides and i

229 It has been suggested that CD4+ T cell proliferative responses to HIV p24 Ag may be import

230 elper lymphocytes, manifested by increased T cell proliferative responses to HIV-1 Gag and recall ant

231 A range of T-cell proliferative responses to HPV-11 VLP were observed

232 ever, it has been difficult to demonstrate T cell proliferative responses to human insulin in IDDM pa

233 Their peripheral blood mononuclear cell proliferative responses to immunogen stimulation 4

234 in, saliva IgA binding to insulin, or CD4+ T-cell proliferative responses to insulin were observed in

235 nd saliva IgA binding to insulin, and CD4+ T-cell proliferative responses to insulin.

236 of 25 tested persons made antigen-specific T cell proliferative responses to L2E7, and peripheral blo

237 fter the transplantation of thymus tissue, T-cell proliferative responses to mitogens developed in fo

238 All 7 survivors developed T-cell proliferative responses to mitogens of more than 10

239 L-12 significantly increased PBMC and CD4+ T cell proliferative responses to p24 Ag in HIV-infected,

240 T cell proliferative responses to purified HHV-8 were meas

241 granule precursor cells and enhances granule cell proliferative responses to Sonic hedgehog.

242 oavailability facilitated the induction of T cell proliferative responses to suboptimal stimuli.

243 ventilatory acclimatization and carotid body cell proliferative responses to sustained hypoxia.

244 T-cell proliferative responses to synthetic peptides demon

245 acrophages and DCs directly regulate human B-cell proliferative responses to T-cell-independent stimu

246 Primary T cell proliferative responses to TCR ligation plus CD28 c

247 Eleven of the 21 patients also developed T cell proliferative responses to the homologous self-Ag.

248 CD4 T cell proliferative responses to the pneumococcal protein

249 s, inhibition of SIV replication, and CD4+ T cell proliferative responses to three of the extracellul

250 T cell proliferative responses to topo I were detected in

251 w also had a reduced capacity to stimulate T cell proliferative responses to tubercle bacillus Ag 85.

252 lidated linear discriminant analysis using T cell proliferative responses to two regions of Tri r 2 (

253 lity to enhance anti-CD3-stimulated CD4(+) T cell proliferative responses via B7-1 and B7-2.

254 endritic cells (DCs) to induce Ag-specific T cell proliferative responses was significantly reduced c

255 ti-IgM- and anti-CD40 plus anti-Ig-induced B cell proliferative responses were decreased in BXD2-Aicd

256 ll as anti-HLA-A2 antibody development and T cell proliferative responses were determined at days +5,

257 delayed-type hypersensitivity and splenic T cell proliferative responses were examined, Peyer's patc

258 Overall, cell proliferative responses were influenced by both the

259 oy islet tissue in vivo though spontaneous T-cell proliferative responses were observed in prediabeti

260 T cell proliferative responses were seen with all encephal

261 Furthermore, specific CD4(+) and CD8(+) T cell proliferative responses were significantly increase

262 These data suggest that Ply induces CD4 T cell proliferative responses with production of IFN- gam

263 on of innate immune responses and adaptive T cell proliferative responses, along with only transient

264 ides containing these sequences stimulated T cell proliferative responses, although less intensely th

265 pecific intrahepatic and peripheral CD4(+) T cell proliferative responses, and cytokines (enzyme-link

266 globulin A (IgA)- and IgG-secreting cells, T-cell proliferative responses, and gamma interferon secre

267 n of maturation markers, IL-12 production, T cell proliferative responses, and IFN-gamma production.

268 They elicited only weak allogeneic T-cell proliferative responses, and repeated stimulation i

269 enhancement in anti-CD3-stimulated CD4(+) T-cell proliferative responses, and this proliferation was

270 timulatory activity for primary and memory T-cell proliferative responses, but this was substantially

271 induced a rapid increase in NK activity, NK cell proliferative responses, generation of lymphokine-a

272 mmaRIIB only modestly affected initial CD4 T cell proliferative responses, suggesting that FcgammaRII

273 h specific impairment of ex vivo antidonor T cell proliferative responses, which was not reversed by

274 ccompanied by diminished antigen-specific, T-cell proliferative responses.

275 or antibody binding and induction of human T-cell proliferative responses.

276 mparable levels of IL-2 and IL-4 and similar cell proliferative responses.

277 al blood lymphocytes and better priming of T-cell proliferative responses.

278 ergic subjects but did not change in vitro T-cell proliferative responses.

279 mia was not associated with an increase in T cell proliferative responses.

280 ted in a significant enhancement of T-helper cell proliferative responses.

281 t spleen APC in vitro leads to normal CD4+ T cell proliferative responses.

282 involved in the ability of FDC to inhibit T-cell proliferative responses.

283 ory mediators, and failed to induce robust T cell proliferative responses.

284 by significant adaptive CD4(+) and CD8(+) T cell proliferative responses.

285 e potency of APCs and boost mitogen-driven T-cell proliferative responses.

286 ncreasing cholesterol efflux suppressed stem cell proliferative responses.

287 the regulation of activated CD4(+) T-helper cell proliferative responses; blocking this interaction

288 , protective GSH is more abundant, and where cell-proliferative responses are better able to sustain

289 Suppression of T cell-proliferative responses during malaria has been att

290 However, B cell-proliferative responses induced by stimulation of t

291 nt than untreated DCs in driving syngeneic T cell-proliferative responses to staphylococcal enterotox

292 a significant increase in PBLs, but T and B cell-proliferative responses were not consistently enhan

293 terized by a lack of virus-specific CD4(+) T-cell-proliferative responses, but strong responses have

294 e absence of strong HIV-1-specific, CD4(+) T-cell-proliferative responses, yet the mechanism underlyi

295 ture DCs were used to stimulate allogeneic T cells, proliferative responses were dampened (approximat

296 n, a G12/13-stimulated pathway implicated in cell proliferative signaling.

297 ortant effects on cell cycle progression and cell proliferative signaling.

298 A differential proteomic analysis of B cell proliferative states, similar to previous transcrip

299 nd, burn injury alone caused a substantial T-cell proliferative suppression at 2 days postburn in bot

300 that can become a potential target for beta-cell proliferative therapies.